XNCR Xencor Inc.

30.25
-0.75  -2%
Previous Close 31
Open 30.83
Price To Book 2.91
Market Cap 1,724,394,777
Shares 57,004,786
Volume 441,201
Short Ratio
Av. Daily Volume 427,924
Stock charts supplied by TradingView

NewsSee all news

  1. Xencor to Present at Upcoming Investor Conferences

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D.,

  2. Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced it will present new preclinical

  3. Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors

    -- XmAb20717 generally well-tolerated and a confirmed complete response (CR) observed at highest dose level tested -- -- Robust, dose-dependent immune activation consistent with inhibition of both PD-1 and CTLA-4

  4. Xencor to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D.,

  5. Xencor Reports First Quarter 2020 Financial Results

    -- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data released October 5, 2018. Primary endpoint not met.
XmAb5871
Systemic Lupus Erythematosus (SLE)
Phase 3 trial to be initiated - partner required.
XmAb5871
IgG4-Related Disease (IgG4-RD)
PDUFA date under priority review August 30, 2020.
Tafasitamab (MOR208/XmAb5574)
Relapsed or refractory diffuse large B cell lymphoma
Phase 1 trial placed on partial clinical hold - February 20, 2019.
XmAb14045
Acute Myeloid Leukemia (AML)
Phase 1 initial data at ASH December 9, 2019 - generally well tolerated.
XmAb13676
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 1 initial data due 2020.
XmAb18087
Neuroendocrine tumors (NET) and gastrointestinal stromal tumors (GIST)
Phase 1 initiation of dosing announced May 6, 2019.
XmAb23104-01 (DUET-3)
Solid tumors
Phase 1 commencement of dosing announced June 3, 2019.
XmAb22841
Solid tumors
Phase 1 initial data due presented at ASCO May 29, 2020.
XmAb20717 (DUET-2)
Solid tumors

Latest News

  1. Xencor to Present at Upcoming Investor Conferences

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D.,

  2. Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced it will present new preclinical

  3. Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors

    -- XmAb20717 generally well-tolerated and a confirmed complete response (CR) observed at highest dose level tested -- -- Robust, dose-dependent immune activation consistent with inhibition of both PD-1 and CTLA-4

  4. Xencor to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D.,

  5. Xencor Reports First Quarter 2020 Financial Results

    -- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and

  6. Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release first quarter

  7. Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced it has entered into a technology

  8. Xencor Reports Fourth Quarter and Full Year 2019 Financial Results

    -- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and

  9. Xencor to Host Fourth Quarter and Full Year 2019 Financial Results Webcast and Conference Call on February 24, 2020

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that it will release fourth quarter

  10. Xencor to Present at Upcoming Investor Conferences

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will

  11. Aimmune Licenses Exclusive Worldwide Rights to Xencor's XmAb®7195 for the Development of Next-Generation Food Allergy Treatments

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced it has granted an exclusive worldwide

  12. Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced it has

  13. Xencor Appoints Dagmar Rosa-Bjorkeson to Board of Directors

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the

  14. Xencor Appoints Allen Yang, M.D., Ph.D., as Senior Vice President and Chief Medical Officer

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the

  15. Xencor Presents Initial Data from Phase 1 Study of XmAb®13676 in B-cell Malignancies at the ASH Annual Meeting

    -- Live webcast to review initial clinical data at 8:30 p.m. EST tonight -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer,

  16. Xencor to Present at Upcoming Investor Conferences

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that

  17. Xencor to Present Initial Data from the Phase 1 Study of XmAb®13676 in B-Cell Malignancies at the American Society of Hematology Annual Meeting

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that

  18. Xencor Reports Third Quarter 2019 Financial Results

    -- Management to Host Conference Call at 4:30 p.m. ET today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune

  19. Xencor to Present at the 2019 Cantor Global Healthcare Conference

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that

  20. Xencor Appoints Celia Eckert as Vice President, General Counsel and Corporate Secretary

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the